Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine ER PK Study in Hepatic Impairment
NCT04020016Phase 1Completed
- Sponsor
- Trevi Therapeutics
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nalbuphine in pruritus, sponsored by Trevi Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Time to Reach Maximum Observed Plasma Concentration at 72 hours and 9 more. Started Jun 2019; status: completed.
02
Drugs
nalbuphine
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT04020016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04020016.